Ankylosing spondylitis is a common form of inflammatory arthritis predominantly affecting the spine and pelvis that occurs in approximately 5 out of 1,000 adults of European descent. Here we report the identification of three variants in the RUNX3, LTBR-TNFRSF1A and IL12B regions convincingly associated with ankylosing spondylitis (P < 5 × 10 −8 in the combined discovery and replication datasets) and a further four loci at PTGER4, TBKBP1, ANTXR2 and CARD9 that show strong association across all our datasets (P < 5 × 10 −6 overall, with support in each of the three datasets studied). We also show that polymorphisms of ERAP1, which encodes an endoplasmic reticulum aminopeptidase involved in peptide trimming before HLA class I presentation, only affect ankylosing spondylitis risk in HLA-B27-positive individuals. These findings provide strong evidence that HLA-B27 operates in ankylosing spondylitis through a mechanism involving aberrant processing of antigenic peptides.
Ankylosing spondylitis is the prototypic spondyloarthropathy, one of a group of conditions which also includes psoriatic arthritis, reactive arthritis and arthritis complicating inflammatory bowel disease. Ankylosing spondylitis is highly heritable (heritability >90%) 1, 2 and familial (sibling recurrence risk ratio >52) 3 . Men are affected 2-3 times more frequently than women. The disease is strongly associated with HLA-B27; however, only 1-5% of HLA-B27-positive individuals develop ankylosing spondylitis, and there is strong epidemiologic evidence to suggest that other genes are involved [2] [3] [4] [5] . Spondyloarthropathy is characterized histopathologically by inflammation involving the attachments of tendons and ligaments to bone (entheses). This initial enthesitis is followed by bone formation, leading to fusion (ankylosis) of the affected joints. Effective treatments are available to suppress the inflammatory component of ankylosing spondylitis, but no treatment has yet been shown to improve its long-term outcome, particularly the loss of movement caused by bony ankylosis. In addition to its strong association with HLA-B27, ankylosing spondylitis has been convincingly associated with loci containing the genes IL23R, ERAP1 and KIF21B and with the 2p15 and 21q22 intergenic regions [6] [7] [8] .
In the current study, as part of the Wellcome Trust Case Control Consortium 2 (WTCCC2), we performed a genome-wide association study of 1,787 British and Australian affected individuals (cases) of European ancestry fulfilling the modified New York criteria for ankylosing spondylitis 9 and 4,800 common controls, following quality control steps. We genotyped cases with the Illumina 660W-Quad microarray and genotyped controls with custom Illumina Human 1.2M-Duo chips. We combined these data with the findings of non-overlapping cases and controls from the Australo-AngloAmerican Spondyloarthritis Consortium (TASC) 6 , establishing a discovery set comprising 3,023 cases and 8,779 controls (Online Methods). We then performed a replication study in an independent cohort including 2,111 cases and 4,483 controls from Australia, Great Britain and The Spondyloarthritis Research Consortium of Canada (SPARCC).
RESULTS

Primary association findings
We saw genome-wide significant association (P < 5 × 10 −8 in the combined discovery and replication datasets) at SNPs close to or within previously established disease-associated loci, including HLA-B, ERAP1, IL23R, KIF21B and the gene deserts 2p15 and 21q22 ( Table 1 and Supplementary Fig. 1 ), as well as at three new loci: RUNX3, IL12B and LTBR-TNFRSF1A ( Table 2) . We also found strong evidence of association for SNPs in or near ANTXR2 (P = 9.4 × 10 −8 ), CARD9 (P = 1.1 × 10 −6 ), PTGER4 (P = 2.6 × 10 −7 ) and TBKBP1 (P = 5.3 × 10 −8 ), with support in all three datasets (Table 2, Supplementary  Fig. 2 and Supplementary Tables 1-3 ). SNPs around two of these loci, ANTXR2 and CARD9, have shown strong evidence of association in previous studies 6, 10 .
To investigate the new associations more closely, we performed further statistical analysis and functional work on RUNX3 and PTGER4. RUNX3 encodes a transcription factor critically involved in CD8 lymphocyte differentiation 11 . Expression of RUNX3 is driven by ; in the current study, we saw moderate association with SNPs in IL7R (rs13172042, P = 8.0 × 10 −5 and rs1993879, Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility P = 9.0 × 10 −5 ). In a previous genome-wide association study of peripheral blood cell subset counts, SNPs in RUNX3 that were associated with ankylosing spondylitis in the current study also showed association with decreased CD8 lymphocyte counts (rs10903118, P = 0.0037, determining 0.42% of CD8 count variance and rs11249215, P = 0.0042, determining 0.41% of CD8 count variance) 12 . Consistent with this observation, we observed that ankylosing spondylitis cases on no biological therapy have lower CD8 lymphocyte counts than age-matched controls ( Supplementary Fig. 3 ), suggesting that the RUNX3 association with ankylosing spondylitis may operate through an effect on CD8 lymphocyte counts.
PTGER4 is a component of the 'mechanostat' anabolic bone response to physical stress, including at the site of insertion of tendons and ligaments into bone (entheses), a site characteristically involved in ankylosing spondylitis. We therefore tested expression of PTGER4 in synovial biopsy samples from spondyloarthritis cases compared with controls (either healthy or with non-inflammatory arthritis) and found increased expression in spondyloarthritis samples (1.9-fold change, P = 0.04, two-tailed test).
Secondary signals at disease-associated loci
To look for regions where the pattern of association is not sufficiently characterized by the most significant SNP, we ran the program GENECLUSTER on the WTCCC2 data 13 . Two loci, ERAP1 and IL23R, showed strong evidence for a second SNP; the Bayes factor, which is the ratio of the probability of the data under a two mutation model relative to a one mutation model 13, 14 , was 12.3 at ERAP1 and 28.8 at IL23R.
At both loci, the pattern of association was consistent with a primary effect at the marginally most significant SNP (rs30187 at ERAP1 and rs11209026 at IL23R) and a secondary effect at a nearby SNP (rs10050860 or rs17482078, two SNPs with r 2 = 1, at ERAP1 and rs11209032 at IL23R). Frequentist analysis conditioning on the primary SNP confirmed the secondary SNP as explaining a significant additional fraction of risk at both loci in both the discovery and replication data (IL23R, rs11209032, WTCCC2 P = 7.9 × 10 −6 , TASC P = 0.0018, replication P = 0.0018; ERAP1, rs10050860, WTCCC2 P = 0.0025, TASC P = 0.026, replication P = 0.00023; Table 3 and Supplementary Fig. 4 ). Around IL23R, the minor allele at rs11209026 (which is inferred to be non-ancestral) is strongly protective, whereas the minor allele of rs11209032 increases disease risk. In ERAP1, the major allele of rs30187 and the minor allele of rs10050860 are protective (and both are inferred to be non-ancestral). In combination, the protective effect was particularly strong; HLA-B27-positive individuals homozygous for protective variants at rs30187 and rs10050860 had approximately 3-4 times lower disease risk than HLA-B27-positive individuals with risk predisposing alleles at these loci ( Supplementary Fig. 4 ).
Major histocompatibility complex (MHC) studies
In addition to our association analyses, we tested genotyped and imputed SNPs across the MHC for their ability to tag HLA-B27. We identified one SNP, rs4349859, that strongly tagged HLA-B27 and had high sensitivity (98.0%) and specificity (99.0%) in 538 cases and 741 controls of European origin from Australia and Great Britain (Supplementary Table 4 ). This SNP also showed the strongest association with ankylosing spondylitis in our study. A second SNP, rs13202464, showed slightly higher sensitivity (98.7%) but slightly lower specificity (98.0%) for HLA-B27 than rs4349859. Further studies will be required to determine the value of typing both SNPs over and above rs4349859 alone to impute HLA-B27 genotype. Controlling for rs4349859 and rs1320464, there were some residual signals in the MHC, which could warrant further investigation, but no other SNP across the MHC achieved P < 4.0 × 10 −6 in the combined discovery and replication datasets. rs4349859 lies 41-kb centromeric of HLA-B and 5.4-kb telomeric of MICA, which neighbors HLA-B. MICA has previously been associated with ankylosing spondylitis 15, 16 ; in order to distinguish whether Top tier SNPs have a combined P < 5 × 10 −8 and lower tier SNPs have combined P ≤ 5 × 10 −6 . Chr., chromosome.
a NCBI human genome build 36 coordinates.
A r t i c l e S our finding was caused by linkage disequilibrium with HLA-B27 or whether it indicated a potential disease-causative variant itself, we tested the ability of rs4349859 to tag HLA-B27 subtypes with differential association with ankylosing spondylitis. These studies confirmed that rs4349859 tags all the major European-ancestry ankylosing spondylitis-associated subtypes, HLA-B Table 4 ). Further, neither rs4349859 nor rs1320464 was more sensitive or specific than HLA-B27 for ankylosing spondylitis in cases and controls typed for each polymorphism in the WTCCC2-TASC dataset (data not shown).
Gene-gene interaction studies
We tested loci known to be associated with ankylosing spondylitis, including those identified in the current study, for gene-gene interaction (defined as a departure from additivity on the log-odds scale). We observed strong evidence for gene-gene interaction between HLA-B27 (as tagged by rs4349859, with a dominant model 20 ) and the nonsynonymous SNP (nsSNP) rs30187 in ERAP1 in the WTCCC2, TASC and replication datasets (WTCCC2 P = 0.02, TASC P = 0.014, replication P = 0.0019, combined P = 7.3 × 10 −6 ; see also Supplementary Table 5 ).
The interaction takes a particularly simple form: in HLA-B27-positive cases and controls, ERAP1 was associated with ankylosing spondylitis, whereas we saw no association with ERAP1 in HLA-B27-negative cases ( Fig. 1) . In contrast, SNPs at other risk loci, including IL23R, KIF21B, IL12B and the intergenic regions 2p15 and 21q22, were associated with ankylosing spondylitis in both HLA-B27-positive and HLA-B27-negative disease (Supplementary Table 6 ). Odds ratios and 95% confidence intervals for each of the possible genotype combinations are presented in Supplementary Table 7 . We tested the robustness of the HLA-B27-ERAP1 interaction by also fitting the full (but less powerful) 4-degree-of-freedom interaction test (Online Methods). We observed evidence for interaction between rs4349859 and rs30187 in the WTCCC2 (WTCCC2 χ 4 2 = 9.77, P = 0.04) and replication cohorts (replication χ 2 = 10.05 (4 degrees of freedom), P = 0.04), whereas the pattern of odds ratios in the TASC dataset indicated a trend in the same direction (TASC χ 4 2 = 7.03, P = 0.13). Combining the evidence across cohorts provided strong evidence for the existence of an interaction (combined χ 4 2 = 23.28, P = 0.0001), showing that our results are robust and are not likely to be an artifact.
Investigation of ERAP1 function
ERAP1 has two reported functions. First, it may act as a 'molecular ruler' within the endoplasmic reticulum, trimming peptides that have been partially processed by the proteosome (typically 9-17 amino acids in length) down to nine amino acids in length, the optimal length for HLA class I binding and presentation 21, 22 . Second, in vitro studies have suggested that ERAP1 may function as a 'sheddase' , cleaving cytokine receptors off the cell surface, including IL-6R, IL-1R2 and TNFR [23] [24] [25] . We tested the ability of ERAP1 to cleave TNFR and IL-6R from cell surfaces by measuring the appearance of these receptors in cell culture supernatants from single-cell suspensions prepared from Erap1 −/− and C57BL/6 control mouse spleens ( Supplementary  Fig. 5 ). We observed no difference in the levels of these receptors over time, indicating that ERAP1 does not have a major influence on cytokine receptor trimming, at least in mice.
In a preliminary in vitro examination of the effects of allelic variants on the function of ERAP1 in peptide trimming, we synthesized recombinant ERAP1 with the wild-type sequence or the ankylosing spondylitis-associated variants p.Lys528Arg (rs30187), p.Arg725Gln (rs17482078) or p.Asp575Asn (rs10050860) and tested their ability to trim an ERAP1 substrate 26 . In the discovery dataset, the second SNP at ERAP1, rs10050860, was in complete linkage disequilibrium with rs17482078. Both the protective rs30187 and rs17482078 alleles had ~40% slower rates of substrate trimming than wild-type ERAP1 (P = 0.050, Wilcoxon rank sum test, one-tailed exact test), suggesting Figure 1 Association findings for the ERAP1 SNP rs30187 stratified by the HLA-B27 tag SNP rs4349859. rs4349859 allele A tags HLA-B27. Error bars, 95% confidence intervals. Note that the ERAP1 risk allele T only increases risk in individuals carrying at least one copy of the HLA-B27 risk allele tag. The odds ratios for the genotype combinations were calculated using logistic regression in the R software package including covariates for ancestry (where appropriate). Genotypes with the low risk CC/GG genotype were set as the baseline, and the other genotype combinations were coded according to a series of dichotomous indicator variables. Odds ratios were derived by exponentiating the relevant coefficient from the logistic regression. that both represent loss-of-function variants (Fig. 2) ; the proteolytic rate of rs10050860 was similar to wild-type ERAP1.
DISCUSSION
This study increases the number of genetic loci convincingly associated with ankylosing spondylitis to nine (IL23R, RUNX3, KIF21B, 2p15, IL12B, ERAP1, HLA-B, LTBR-TNFRSF1A and 21q22), identifies a further four loci that show strong evidence of association and are likely to be involved in disease pathogenesis (ANTXR2, PTGER4, CARD9 and TBKBP1) and greatly expands our understanding of the etiopathogenesis of the condition, including the likely mechanism by which HLA-B27 operates in the disease. These new genetic findings further implicate the involvement of the IL-23-IL-23R-IL-17 pathway in ankylosing spondylitis. Although further studies will be required to identify the true disease-associated variants, each associated locus contains candidate genes of strong biological interest in ankylosing spondylitis, which are discussed below. IL12B encodes IL12p40, which is a shared component of both IL-12 and IL-23. Association has previously been reported between SNPs in IL23R and ankylosing spondylitis 7 . SNPs in or near CARD9 and PTGER4 (encoding prostaglandin E receptor 4, EP4 subtype) have also been associated with Crohn's disease previously 27, 28 , and variants within IL12B and IL23R have been associated with both Crohn's disease and psoriasis [29] [30] [31] . PGE 2 acts through PTGER4 to induce the production of IL-23 and IL-17 and to promote expansion of T H 17 lymphocyte counts; T H 17 lymphocyte counts and IL-17 levels are both known to be elevated in ankylosing spondylitis 32 . Consistent with this, we observed upregulation of PTGER4 expression in spondyloarthritis synovium. CARD9 mediates signals from dectin-1 and -2, which are innate immunity receptors for β-glucan, a component of fungal and some bacterial cell walls. β-glucan induces PGE 2 production, which in turn promotes the expansion of T H 17 cells 33 . We and others have recently reported that SKG mice treated with β-glucan develop spondyloarthritis and Crohn's disease 34 ; this mouse model is characterized by T H 17 activation 35 . These findings are thus consistent with a model of human ankylosing spondylitis in which ubiquitous pathogens carrying β-glucan induce disease by stimulating the IL-23-IL-23R-IL-17 pathway. Despite considerable research since the discovery of the association of HLA-B27 with ankylosing spondylitis in the early 1970s, the mechanism explaining the involvement of HLA-B27 with the disease is unclear. Current theories can essentially be divided into those that favor canonical functions of HLA-B27 in peptide presentation (the 'arthritogenic peptide' theory) and those that invoke aberrant properties of HLA-B27 itself, including the propensity to form HLA-B27 homodimers and/or induce endoplasmic reticulum stress caused by slow and inefficient folding of nascent HLA-B27 molecules. A further possible hypothesis is that HLA-B27 acts as a tag for another, nearby, true susceptibility allele. Our findings that no other MHC SNP was more strongly associated with ankylosing spondylitis than rs4349859 or HLA-B27 indicate that this 'linked gene' theory is unlikely. The finding that rs4349859 does not tag HLA-B27 subtypes common in Asian populations but does tag HLA-B*2709, a European HLA-B27 subtype not associated with ankylosing spondylitis, indicates that rs4349859 is not disease causative in its own right. However, it does tag the ancestral HLA-B*2705 subtype, and other European HLA-B27 subtypes, with high sensitivity and specificity within the level of accuracy of HLA-B27 typing itself but at far lower cost and difficulty.
The interaction between HLA-B27 and ERAP1 is also highly informative regarding potential mechanisms of disease in ankylosing spondylitis. The restriction of the association of ERAP1 with ankylosing spondylitis to HLA-B27-positive cases is consistent with disease models in which aberrant trimming of peptides or presentation by ERAP1 and HLA-B27 are involved in the pathogenesis of HLA-B27-associated disease. HLA-B27-and ERAP1-negative disease is unlikely to be caused by a similar mechanism, and the fact that overexpression of TNF alone is sufficient to cause spondyloarthritis in mice 36 suggests that overexpression or signaling by pro-inflammatory cytokines alone may be sufficient to cause ankylosing spondylitis. Although the findings of our studies of ERAP1 function using recombinant ERAP1 protein require much further experimental validation, they suggest that ERAP1 influences disease risk in ankylosing spondylitis, with associated, non-ancestral alleles reducing the disease risk by a mechanism involving reduced peptide trimming and, likely as a consequence, altered peptide presentation by HLA-B27. This finding, and the strong protective effect of ERAP1 variants in ankylosing spondylitis, suggest that inhibition of ERAP1 may be effective in ankylosing spondylitis, at least in HLA-B27-positive disease.
Modeling studies in ankylosing spondylitis 3 and in many other common diseases 37, 38 , as well as findings in many plant and animal species, suggest that the best genetic models for common diseases involve gene-gene interaction. Very few well-replicated examples of gene-gene interaction in common polygenic diseases have been reported to date, making the finding of interaction between HLA-B27 and ERAP1 in ankylosing spondylitis of particular interest. A similar observation was made in the overlapping WTCCC2 study of psoriasis 39 , with gene-gene interaction observed between ERAP1 and HLA-Cw6.
We present here the first convincing evidence of associations in HLA-B27-negative ankylosing spondylitis. HLA-B27-negative ankylosing spondylitis has very similar clinical presentation and disease course as HLA-B27-positive disease, with a similar natural history but with a later age of onset and lower incidence of uveitis 40, 41 . Few families have been reported with recurrence of ankylosing spondylitis in the absence of HLA-B27, no studies have examined the heritability of ankylosing spondylitis in its absence and no loci have previously been convincingly associated with ankylosing spondylitis in HLA-B27-negative cases, probably because only small studies have been performed addressing this. Our findings indicate both substantial overlap and differences in genetic susceptibility between HLA-B27-positive and -negative ankylosing spondylitis and suggest a shared etiopathogenesis.
This study provides further evidence of the involvement of TNF pathways in ankylosing spondylitis pathogenesis. TNF antagonists are highly effective in suppressing inflammation in ankylosing spondylitis, and mice overexpressing TNF develop spondyloarthritis 36 . In the current study, we observed association with SNPs at chromosome 12p13 between LTBR (lymphotoxin beta receptor) and TNFRSF1A (tumor necrosis factor receptor 1 (TNFR1)) (rs11616188, WTCCC2 P = 1.2 × 10 −5 , TASC P = 6.2 × 10 −8 , replication P = 0.0036, combined P = 4.1 × 10 −12 ) (Supplementary Fig. 2 ). A mouse model with constitutive overexpression of TNF that develops inflammatory bowel disease and spondyloarthritis has been reported, in which the arthritis has been shown to be dependent on TNFR1 expression and in which TNFR1 expression in mesenchymal tissue alone is sufficient to permit disease 36 . This is consistent with a role for TNFR1 in ankylosing spondylitis, but further studies will be required to determine if the genetic polymorphisms at this locus are associated with ankylosing spondylitis because of effects on LTBR, TNFRSF1A or both. We also observed association at chromosome 17q21 near TBKBP1 (encoding TBK binding protein 1), a component of the TNF receptor signaling pathway (rs8070463, WTCCC2 P = 0.0025, TASC P = 1.6 × 10 −5 , replication P = 0.015, combined P = 5.3 × 10 −8 ) (Supplementary Fig. 2) . TRADD, which has previously shown suggestive association 6, 42 and which also shows suggestive association with ankylosing spondylitis in this study encodes the TNF-receptor-associated death domain protein, also part of the TNF signaling pathway (rs9033, WTCCC2 P = 9.0 × 10 −6 , TASC P = 0.32, combined P = 4.9 × 10 −5 ). Further research will be required to determine the precise mechanism underlying these associations. The association of SNPs in and around RUNX3 provides further support for the hypothesis that HLA-B27 is involved in ankylosing spondylitis by a mechanism involving peptide presentation. The canonical function of HLA class I molecules is to present antigen to CD8 lymphocytes. RUNX3 is a key gene involved in CD8 lymphocyte differentiation, and we have shown here that ankylosing spondylitis cases have reduced CD8 lymphocyte counts and that the RUNX3 SNPs associated with ankylosing spondylitis are also associated with reduced CD8 lymphocyte counts in healthy individuals. These findings are consistent with a key role for CD8 lymphocytes in ankylosing spondylitis pathogenesis, likely in response to antigenic peptides presented by HLA-B27.
In conclusion, this study has identified further non-MHC genetic loci associated with ankylosing spondylitis. Our data strongly imply that HLA-B27 itself, rather than a nearby linked gene, is directly involved in ankylosing spondylitis susceptibility. We have also shown that HLA-B27-positive and -negative ankylosing spondylitis cases differ in association with ERAP1, which is involved in endoplasmic reticulum peptide processing before HLA class I assembly and peptide presentation. This represents one of the first convincingly replicated examples of gene-gene interaction in any common disease and indicates that the likely mechanism by which HLA-B27 induces ankylosing spondylitis involves aberrant presentation or handling of peptides.
URLs. SNPTEST, http://www.stats.ox.ac.uk/~marchini/software/ gwas/snptest.html; HapMap, http://hapmap.ncbi.nlm.nih.gov/.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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ONLINE METHODS
Samples. For cases, ankylosing spondylitis was defined according to modified New York criteria 9 . A total of 1,787 DNA samples from unrelated individuals of European ancestry were included in the GWAS discovery set, having passed genotyping control filters (see below and Supplementary Table 8 ).
The replication set was derived from individuals with ankylosing spondylitis recruited from the UK, Australia and Canada; 2,011 DNA samples passed quality control for replication. All case participants gave written, informed consent, and the study was approved by the relevant research ethics authorities at each participating center.
For controls, a total of 4,800 individuals from the WTCCC2 common control set passed the quality control filters (see below) and were used in the discovery GWAS. This included 2,485 healthy blood donors from the UK Blood Service (UKBS) collection and 2,315 individuals from the 1958 Birth Cohort dataset (see below and Supplementary Table 8 ). The number of replication control samples passing quality control totaled 4,483, comprising 2,831 from the People of the British Isles collection and 1,652 Canadian controls.
GWAS genotyping.
Following careful DNA quality control, including gender verification by genotyping in comparison with patient data manifests, samples were genotyped at the Wellcome Trust Sanger Institute on the Illumina Infinium platform. Samples from the case collection were genotyped on the Human660W-Quad (a custom chip designed by WTCCC2 and comprising Human550 and a set of ~6,000 common copy number variants from the Structural Variation Consortium 43 ). Samples from the control collections were genotyped on the Human1.2M-Duo (a WTCCC2 custom array comprising Human1M-Duo and the common copy number variant content described above). Bead intensity data was processed and normalized for each sample in BeadStudio; data for successfully genotyped samples was extracted and genotypes were called within collections using Illuminus 44 .
GWAS quality control.
We identified and removed samples whose genomewide patterns of diversity differed from those of the collection at large, interpreting them as likely to be caused by biases or artifacts. To do so, we used a Bayesian clustering approach to infer outlying individuals on the basis of call rate, heterozygosity, ancestry and average probe intensity. To obtain a set of putatively unrelated individuals, we used a Hidden Markov model to infer identify by descent along the genome and then iteratively removed individuals to obtain a set with pairwise identity by decent less than 5%. These methods are described elsewhere 39, 45 . Sample exclusions before imputation are outlined in Supplementary Table 8 .
For SNPs, a measure of (Fisher) information for the allele frequency at each SNP was calculated using SNPTEST (see URLs). Autosomal SNPs were excluded if this information measure was below 0.975, if the minor allele frequency was less than 0.1%, if the SNP had >2% missing data or if the Hardy-Weinberg P value was lower than 5 × 10 −20 in the case data or in either of the control collections.
Imputation. For WTCCC2 data, genotypes were imputed using IMPUTE2 (ref. 46) , which adopts a two-stage approach using both haploid and diploid reference panels. For the haploid reference panel, we used HapMap2 and HapMap3 SNP data for the 120 non-related CEU trios (see URLs). For the diploid reference panel, we used 1958 Birth Cohorts and UK Blood Service control data, merging genotypes from the Illumina 1.2M Duo chip and the Affymetrix Genome Wide Human SNP array 6.0. Prior to analysis with IMPUTE2, we applied standard quality control filters akin to those described above. To further protect against potential errors misleading the imputation and phasing, we checked that each genotype conformed to local patterns of linkage disequilibrium in HapMap by using a leave-one-out imputation strategy. Specifically, we ran IMPUTE 46 on each of the study samples in turn, both cases and controls, re-imputing known genotypes. Control individuals for which the imputed genotypes were more than 4.5% discordant with the original genotype were removed. The same rule was applied to case individuals with a discordance threshold of 6%. SNPs for which IMPUTE was confident of the imputation call but for which the genotyped data was discordant (and therefore indicative of genotyping error) were also removed if the difference between the measure of information and error rate was greater than 0.05. The final dataset comprised 1,787 cases and 4,800 controls.
After merging the imputed and genotyped data, we used the program SNPTEST to perform frequentist tests of association at each SNP under a missing data logistic regression model. Unless otherwise stated, we assumed a multiplicative model for allelic risk by encoding the genotypes at each SNP as a discrete explanatory variable with an indicator of case status as the binary response. P values were calculated using the score test implementation in SNPTEST. SNPs for which the (Fisher) information measure, as calculated by SNPTEST, was <0.85 in the case collection or <0.95 in either of the control groups were removed from the analysis. We also removed SNPs for which the equivalent observed (Fisher) information about the parameter describing the risk associated with the individual's genotype was <0.85. Both of these quality control steps exclude SNPs with high missingness rates or uncertain genotypes. Only SNPs with a minor allele frequency >1% were used for subsequent analyses. Evidence for population stratification was minimal in the WTCCC2 discovery set (λ = 1.056), so covariates reflecting ancestry were not included in association models (Supplementary Table 9 and Supplementary Fig. 6 ).
For TASC data, findings from the discovery GWAS were combined with previously reported results from 1,236 non-overlapping cases and 3,979 controls from TASC 6 . Data from the TASC discovery sets were imputed with Markov Chain Haplotyping software (MACH) using phased data from CEU individuals from release 22 of the HapMap project as the reference set of haplotypes 47 . Only SNPs common to cases and controls were used for imputation. Only SNPs that could be imputed with relatively high confidence (R 2 > 0.3) and had a minor allele frequency >1% were used in subsequent analyses. Association analysis of imputed SNPs was performed assuming an underlying additive model with the use of the software package MACH2DAT, which regresses affection status against expected dosage at each imputed locus 47 . Analysis of genotyped SNPs was performed using logistic regression in PLINK 48 . As the evidence of population stratification was appreciable in the TASC discovery set, the first four components from an EIGENSTRAT principal components analysis were included as covariates in the model, as has been described previously 6 . After correction, the TASC data had an inflation factor of λ = 1.025 (Supplementary Table 9 and Supplementary Fig. 6 ).
Meta-analysis.
Prior to analysis, further checks were made to exclude any cryptic sample duplication within, or between, TASC and WTCCC2 cases and controls, leading to the exclusion of a further 13 samples. In total, the sample and SNP exclusions described above resulted in the association analysis of 3,023 cases and 8,779 controls at 2,223,620 autosomal SNPs. To combine the evidence of association across the TASC and WTCCC2 data, we conducted a fixed effect meta-analysis at SNPs present in both datasets. To do so, we averaged the estimated effect size parameter associated with genotype risk across the two datasets, weighted by the inverse of the variance in the estimates. P values were calculated assuming the square of the combined data z-score was distributed as χ 2 with 1 degree of freedom. As an additional quality control step, we compared the estimated effect size in each dataset to the meta-analysis estimate using Cochran's Q, excluding SNPs with heterogeneity P < 0.01. These analyses were conducted using the statistical package R 49 .
Replication genotyping and quality control. Genotyping was carried out at the Wellcome Trust Sanger Institute using the Sequenom iPLEX Gold assay. Individual samples were excluded from analysis if they had call rates <90% or if the reported gender was discordant with sex-specific markers. We removed pairs of samples showing concordance indicative of being duplicates with individuals in the replication and/or discovery sets.
Replication and combined analysis. Association in the replication cohort was performed using logistic regression assuming an additive model and including a dichotomous covariate reflecting Canadian ancestry. Analyses were also performed in the statistical package R. We report replication P values for the likelihood ratio test comparing the models with and without a SNP effect on risk, which is a two-tailed test on the direction of the effect.
Interaction, conditional and haplotype analyses. Results from the WTCCC2-TASC meta-analysis and the replication data were combined using the fixed effect model described above. Frequentist conditional analysis was performed by including the primary SNP as a covariate in the
